Abingworth closes Fund IV at $350m

The Anglo-American life sciences VC firm has exceeded the original $275m target for their Abingworth Bioventures IV fund (ABV IV), which was more than two times over-susbscribed.

ByPEI Staff

30 December 2012•3 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

North America Western Europe

Abingworth closes Fund IV at $350m

Abingworth

Altor Equity Partners

Graphite Capital

IK Partners

Sequoia Capital

Related articles